Zoetis Inc. (NYSE:ZTS), the world's leading producer of pet medicines, has faced a turbulent market, posting a -35.34% return this year and a -16.56% return over the last three months. However, the company reported an 18% year-over-year growth in its companion animal products for Q1 2022 and maintains a robust dividend strategy, recently raising its payout by 30% in 2021. With a market capitalization of $74.2 billion, Zoetis continues to attract hedge fund interest, as evidenced by Bristol Gate Capital's stake valued at over $97.4 million, despite a recent Zacks Rank of #4 (Sell).
“Zoetis Inc. · is the world’s largest producer of · medicines for pets · true”
“Zoetis Inc. · raised its dividend by · 30% · in 2021”
“Zoetis Inc. (NYSE:ZTS) · is · the world’s largest producer of medicines for pets”
“Zoetis Inc. (NYSE:ZTS) · reported · an 18% year-over-year growth in its companion animal products · in Q1 2022”
“Zoetis Inc. (NYSE:ZTS) · pays · a quarterly dividend of $0.325 per share”
“Zoetis Inc. (NYSE:ZTS) · raised · its dividend by 30% · in 2021”
“Zoetis Inc. (NYSE:ZTS) · raised · its dividend at a CAGR of 36% · in the last three years”
“Zoetis Inc. (NYSE:ZTS) · has · a five-year dividend growth rate of 15%”
“Bristol Gate Capital · held · a collective stake worth over $97.4 million in Zoetis Inc. (NYSE:ZTS)”
“Zoetis Inc. (NYSE:ZTS) · is · the world’s largest producer of medicines for pets”
“Zoetis Inc. (NYSE:ZTS) · reported · an 18% year-over-year growth in its companion animal products · Q1 2022”
“Zoetis Inc. (NYSE:ZTS) · pays · a quarterly dividend of $0.325 per share”
